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Tuberculosis (TB), caused by the bacteriumMycobacterium tuberculosis, is the leading cause of mortality worldwide due to a single
infectious agent. The pathogen spreads primarily via aerosols and especially infects the alveolar macrophages in the lungs. The lung
has evolved various biological mechanisms, including oxidative stress (OS) responses, to counteract TB infection. M. tuberculosis
infection triggers the generation of reactive oxygen species by host phagocytic cells (primarily macrophages). The development
of resistance to commonly prescribed antibiotics poses a challenge to treat TB; this commonly manifests as multidrug resistant
tuberculosis (MDR-TB). OS and antioxidant defense mechanisms play key roles during TB infection and treatment. For
instance, several established ﬁrst-/second-line antitubercle antibiotics are administered in an inactive form and subsequently
transformed into their active form by components of the OS responses of both host (nitric oxide, S-oxidation) and pathogen
(catalase/peroxidase enzyme, EthA). Additionally, M. tuberculosis has developed mechanisms to survive high OS burden in the
host, including the increased bacterial NADH/NAD+ ratio and enhanced intracellular survival (Eis) protein, peroxiredoxin,
superoxide dismutases, and catalases. Here, we review the interplay between lung OS and its eﬀects on both activation of
antitubercle antibiotics and the strategies employed by M. tuberculosis that are essential for survival of both drug-susceptible
and drug-resistant bacterial subtypes. We then outline potential new therapies that are based on combining standard
antitubercular antibiotics with adjuvant agents that could limit the ability of M. tuberculosis to counter the host’s OS response.
1. Introduction to Tuberculosis
Tuberculosis (TB) is the leading cause of mortality world-
wide due to a single infectious agent, killing approximately
1.67 million people in 2016 alone [1, 2]. There were an
estimated 10.4 million new cases of the disease globally in
2016, corresponding to an annual incidence rate of approxi-
mately 140 per 100,000 persons [1]. The highest incidence
rates of TB were seen in South Africa (781/100,000), Lesotho
(724/100,000), and the Philippines (554/100,000) in 2016 [1].
Five countries recorded more than 0.5 million new cases
nationally and accounted for >50% of the global total in
Hindawi
Oxidative Medicine and Cellular Longevity
Volume 2018, Article ID 7695364, 10 pages
https://doi.org/10.1155/2018/7695364
2016, i.e., India (2,790,000 cases), Indonesia (1,020,000
cases), China (895,000 cases), Philippines (573,000 cases),
and Pakistan (518,000 cases) [1].
The World Health Organization (WHO) has set End TB
Strategy targets to reduce global TB mortality by 95% and the
incidence of TB by 90% to less than 10 cases per 100,000 by
2035, with respect to 2015 levels [3]. While industrialised
countries such as Australia are considered to have a low TB
burden (incidence rate of 5.7/100,000 nationally in 2014
[4]), the WHO has also established speciﬁc targets for low
TB incidence countries for the pre-elimination of TB by
2035 (deﬁned as <10 TB cases per million population) and
the elimination of TB by 2050 (<1 TB case per million
population) [5]. Reaching targets for the elimination of TB
will require major advances in our understanding of the
biology of the disease, as well as improvements in the
eﬀectiveness and accessibility of preventive, diagnostic, and
therapeutic interventions.
2. Pathogenesis of Tuberculosis
TB in humans is primarily caused by the bacterial species,
Mycobacterium tuberculosis, but can also be caused by other
members of the M. tuberculosis complex (MTBC), including
M. africanum and M. bovis. It is primarily spread via the
release of aerosols from the lungs of patients with active TB
through coughing, sneezing, or spitting. Infection of a new
host commences following inhalation of droplets containing
the pathogen deep into the air sacs of the lungs. There, the
bacterium becomes internalized by resident alveolar macro-
phages.M. tuberculosis is able to prevent phagosome matura-
tion and, hence, fusion with lysosomes [6, 7], which enables
the pathogen to persist inside the macrophage [8]. At this
stage, active TB is not inevitable. In most individuals who
become infected with M. tuberculosis, a latent infection
ensues whereby bacteria are maintained in a low replicative,
but viable, state in the lung with minimal clinical signs or
symptoms evident [9, 10].
In 2016, Houben and Dodd determined the proportion of
the world’s population that are latently infected with TB to be
23.0% (95% uncertainty interval [UI]: 20.4%–26.4%), or
approximately 1.7 billion people [11]. However, the high-
carriage rate provides a reservoir for subsequent disease in
susceptible hosts whereby the age-weighted lifetime risk of
the development of clinical TB in a latently infected individ-
ual has been estimated to be 12% [12]. Furthermore, large
numbers of people develop active TB every year following
recent close contact with an index TB case [13].
If the infected macrophage is unable to contain the
replication ofM. tuberculosis, a granulomatous inﬂammatory
disease results. Here, additional macrophages surround the
infected macrophage and fuse to generate a multinucleated
giant cell [14]. Mature human tubercular lesions have been
found to consist of a central zone of caseous necrotic tissue
bordered by T lymphocytes and macrophages and an area
that also includes aggregates of B cells [14]. The ongoing
inﬂammation can lead to a remodelling of the lung architec-
ture, which manifests as extensive ﬁbrosis, cavitation, trac-
tion bronchiectasis, bronchostenosis, or parenchymal lung
destruction [15, 16]. The pathology caused by TB results in
signiﬁcant lung function impairment as measured by a forced
expiratory volume in 1 second FEV1 < 60% predicted at
diagnosis [17]. In addition to dyspnea, additional symptoms
of active TB include fever, night sweats, and weight loss.
Without appropriate chemotherapy, untreated smear-
positive TB in HIV-negative individuals has a 10-year case
fatality between 53% and 86%, with a weighted mean of
70% [18].
Even after successful adherence to and completion of TB
treatment, former patients may develop long-term airﬂow
obstruction and a restrictive loss of pulmonary function. A
large, international population-based study, Burden of
Obstructive Lung Disease (BOLD), investigated the associa-
tion of airﬂow obstruction and spirometric restriction with
a history of TB. Examining a study population of 14,050
participants from 18 countries, the study established that a
self-reported history of TB was signiﬁcantly associated with
both airﬂow obstruction (adjusted OR of 2.51 [95% CI:
1.83–3.42]) and spirometric restriction (adjusted OR of 2.13
[95% CI: 1.42–3.19]) [19]. The authors of the BOLD study
concluded that a history of TB “should be considered as a
potentially important cause of obstructive disease and low
lung function, particularly where TB is common” [19].
Therefore, identiﬁcation of the speciﬁc mechanisms and
events that lead to lung tissue damage in TB patients is
essential for tempering the impact of the disease.
3. Effect of Oxidative Stress on the Lungs
Oxidative stress (OS) arises due to an imbalance between the
free reactive oxygen species (ROS) and the antioxidant mech-
anisms [20, 21]. In the lung, there is a higher risk of OS com-
pared to other organs [22]. Under physiological conditions,
the lung is exposed to approximately 10–15,000 litres of air
every day, each breath containing a myriad of exogenous
oxidative compounds, such as pollutants, tobacco smoke,
and allergens [23]. All of these exogenous factors stimulate
inﬂammatory cells to generate free radicals [20, 24]. More-
over, under these circumstances, enzyme reaction pathways,
such as nicotinamide adenine dinucleotide phosphate
oxidases, myeloperoxidase, xanthine oxidase, and eosinophil
peroxidase, are activated to produce endogenous ROS,
including hydrogen peroxide, hydroxyl radical, and superox-
ide radical [24]. In order to compensate this burden, the lung
has evolved numerous antioxidant defense mechanisms.
There are two distinct groups of antioxidant processes:
enzymatic and nonenzymatic systems. Enzymatic antioxi-
dant processes present in the lung include superoxide
dismutases (SOD), glutathione peroxidase, and catalase,
whereas nonenzymatic processes involve ferritin, ascorbic
acid ceruloplasmin, and carotene [24–26]. Together, these
antioxidant mechanisms buﬀer oxidants and maintain the
oxidative balance in the lung. However, it is important to
note that such complex antioxidant mechanisms can be
overwhelmed if the production of ROS is greater than the
capacity of cells to scavenge it, leading to OS [20, 24].
Excess formation of ROS can initiate series of chemi-
cal reactions and cause damage to cellular components,
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including proteins, lipids, and nucleic acids [20, 24, 25].
Furthermore, ROS can also initiate inﬂammatory signaling
cascades via protein kinase pathways, transcription factors,
and genomic expression of proinﬂammatory regulators,
leading to an overactivated immune system [27]. Numerous
studies have linked OS to various lung disorders, including
asthma, chronic obstructive pulmonary disease (COPD),
acute pulmonary distress syndrome, and TB [28, 29]. For
instance, airway smooth muscle cells isolated from patients
with COPD had elevated ROS levels compared to healthy
individuals [30]. Likewise, asthmatic patients had higher
levels of oxidant products, including peroxidase, chlorotyro-
sine, malondialdehyde, and bromotyrosine [28]. Patients
suﬀering from acute respiratory distress syndrome exhibit
an oxidant : antioxidant imbalance, as well as high levels of
peroxidase and oxidized α1-antitrypsin [28].
4. Oxidative Stress Response against
Mycobacterium tuberculosis Infection
It is noteworthy that OS is a double-edged sword and
proceeds in an indiscriminate chemical manner. Although
ROS can damage the host cells, it also kills infectious agents,
including invading pathogens within the host. At the molec-
ular level, excess OS causes damage to foreign pathogens via
direct binding of ROS to amino-acid side chains like arginine,
threonine, lysine, and proline and/or histidine oxidation or
modiﬁcation of tyrosine to nitrotyrosine, aﬀecting the struc-
tural and functional properties of proteins [31]. ROS is highly
toxic to bacteria as it can either directly destroy DNA,
protein, and lipids or indirectly damage the nucleic acid via
oxidation of the nucleotide pool [32]. Such damage is
reported to be due to the interaction of ROS and bacteria
via various biochemical processes, including the Fenton
reaction and the tricarboxylic acid cycle [32].
Furthermore, excess ROS production can trigger a series
of oxidative reactions on polyunsaturated fatty acids present
on the cell membrane of microorganism(s), collectively
known as lipid peroxidation [31]. These reactions can
critically destabilise and impair microorganisms’ homeosta-
sis [31]. Hence, the human body generates a balanced
amount of ROS as an antimicrobial defense arsenal against
pathogens. For example, innate immune cells, such as
neutrophils, employ an immune process known as respira-
tory burst as an antimicrobial defense against Candidiasis
by rapid production and release of ROS onto the invading
Candida albicans [33].
M. tuberculosis invades and replicates within the host
macrophages. As an immune response, the infected
macrophage initiates a respiratory burst and produces high
levels of ROS to counteract and kill the mycobacteria [34].
Upregulated serum levels of malondialdehyde (an indicator
for lipid peroxidation) are observed in patients with M.
tuberculosis disease compared to healthy controls [34]. It is
important to point out that the survivability ofM. tuberculo-
sis is highly dependent on the levels of ROS produced by the
host immune cells [35]. If the ROS levels are overwhelmed by
M. tuberculosis antioxidant systems, then the pathogen will
continue to survive and replicate in the host [35].
Mechanistically, among all the ROS, nitric oxide (NO) is
known to be one of the major contributors as an anti-TB
agent. NO is synthesized by NO synthase in macrophages,
and NO synthase-deﬁcient mice have been shown to exhibit
increased susceptibility to M. tuberculosis [36]. Patients with
active pulmonary TB have higher levels of NO in their lungs
[36]. The accumulation of ROS during OS can further pro-
duce superoxide, hydrogen peroxide, and hydroxyl radicals
via single-electron reduction chain reactions [32]. Although
studies have reported thatM. tuberculosis possesses bacterial
SODs and catalases that are known to degrade superoxide
and hydrogen peroxide, respectively, there is no counterme-
chanism for hydroxyl radicals [32]. Interestingly,M. tubercu-
losis responds to ROS in a concentration-dependent manner.
Exposure of M. tuberculosis to a low concentration of ROS
(0–5.0mM hydrogen peroxide) had no eﬀect on the bacterial
cell viability, but it initiated the expression of responsive
genes which are sensitive to ROS [37], whereas high concen-
trations of ROS (50–200mM hydrogen peroxide) were found
to be lethal to M. tuberculosis cells [37]. Collectively, when
the levels of ROS produced by host cells are low,M. tubercu-
losis triggers the release of DNA damage-responsive genes
that initiate DNA repair mechanisms within the bacteria to
counteract the damage done by ROS [37, 38]. However, such
counteractive mechanisms of M. tuberculosis do not protect
against high levels of ROS [37, 38].
5. Chemotherapy of Tuberculosis
The standard therapeutic regimen for drug-susceptible
pulmonary TB recommended by the WHO requires patients
to take four drugs: isoniazid, rifampicin, pyrazinamide, and
ethambutol for 2 months, followed by continuation with iso-
niazid and rifampicin for an additional 4 months (2HRZE/
4HR) [39]. This is a lengthy treatment duration for a bacterial
disease, and clinical trials are in progress to identify an
eﬀective, shortened regimen. This includes the bedaquiline,
pretomanid, moxiﬂoxacin, and pyrazinamide (BPaMZ)
regimen and the bedaquiline, pretomanid, and linezolid
(BPaL) combination, which are currently in advanced phase
2 clinical trials through the TB Alliance (https://www.
tballiance.org/).
Another driver for the development of new regimens to
manage TB is the emergence of MDR-TB that are resistant
to the key ﬁrst-line drugs, isoniazid and rifampicin. There
was an approximate 95% increase in estimated MDR-TB
cases from 250,000 per year in 2009 to 490,000 cases per year
in 2016 [40]. In addition, there were an additional 110,000
cases that were susceptible to isoniazid but resistant to
rifampicin in 2016 [1]. Countries with the highest proportion
of new TB cases being MDR are located in the WHO
European region, where an estimated 71,000 incident cases
of rifampicin-resistant TB and MDR-TB emerged in 2016
[41]. For example, in Belarus, 38% of new TB cases and
72% of previously treated cases in 2016 were MDR [1]. This
is followed closely by the Russian Federation, where 27% of
new TB cases and 65% of previously treated cases were
MDR in the same period [1].
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MDR-TB is diﬃcult and costly to treat. The treatment
completion success rate drops from 83% overall for TB to
54% for MDR-TB cases globally due to a higher frequency
of treatment failure, loss to follow-up, and death of patients
[1]. Furthermore, the estimated costs associated with treating
a case of TB increase substantially when going from drug-
susceptible TB (USD $17,000 in the USA, €10,282 in 15
European Union (EU) countries, per case) to MDR-TB
(USD $134,000 in the USA, €57,213 in 15 EU countries,
per case) [42, 43]. The standard treatment for MDR-TB
recommended by the WHO has consisted of an intensive
8-month phase with at least ﬁve eﬀective TB drugs, which
included pyrazinamide (group D1) and at least four core
second-line drugs: one from group A, one from group B,
and at least two drugs from group C (Table 1). When
the drug-susceptibility proﬁle of the isolate or drug toxicity
in the patient prevents the minimum number of ﬁve eﬀective
TB drugs, drugs from group D2 and D3 are added to
bring the total to ﬁve [44]. This is then followed by a
continuation phase, with at least three of the second-line
anti-TB drugs that are most potent against the speciﬁc
patient isolate of M. tuberculosis, for a total treatment
duration of 20 months [44]. In 2016, the WHO updated
its treatment guidelines and recommended a shorter 9- to
12-month treatment duration for MDR-TB based on its
successful use in Bangladesh and several other countries
[45]. Here, the regimen consists of a 4- to 6-month intensive
phase with seven drugs, i.e., moxiﬂoxacin (group A),
kanamycin (group B), prothionamide (group C), clofazimine
(group C), pyrazinamide (group D1), high-dose isoniazid
(group D1), and ethambutol (group D1), followed by a 5-
month continuation phase with moxiﬂoxacin, clofazimine,
pyrazinamide, and ethambutol [45]. This newer regimen
decreases the cost of MDR-TB treatment and is expected to
reduce patient loss from therapy.
TB treatment is associated with levels of toxicity in
patients, in some cases, requiring discontinuation of spe-
ciﬁc drugs. The ﬁrst-line drugs isoniazid and pyrazinamide
are associated with hepatotoxicity [46]. Along with rifam-
picin, they are also associated with gastrointestinal upset
and rash [46]. Ethambutol, on the other hand, can cause
ocular toxicity [47, 48]. In terms of second-line TB drugs,
moxiﬂoxacin and other ﬂuoroquinolones carry a risk of
lengthening the QT interval in the heart’s electrical cycle
[49]. Kanamycin and other second-line aminoglycosides,
which require parenteral injection, are associated with
hearing loss, nephrotoxicity, skin rash, hypersensitivity,
and peripheral neuropathy [49]. Prothionamide causes
gastrointestinal disturbance, including vomiting, while
clofazimine can lead to skin discolouration and QT pro-
longation [49]. It is therefore apparent that there is still
a need to improve the therapeutic management of TB—to
increase the eﬃcacy of TB drugs to further reduce the
duration of treatment and to minimise adverse side eﬀects
for patients.
6. Role of Oxidative Processes in the
Activation of TB Prodrugs
Several of the TB drugs are administered to patients in an
inactive form and must be activated inside the host. One of
those is isoniazid (isonicotinylhydrazide). This prodrug is
oxidatively activated by a catalase/peroxidase enzyme present
in M. tuberculosis, KatG, to produce an isonicotinic acyl
radical [50]. This couples with NAD+ and NADP+ to form
a number of adducts which inhibit a 2-trans-enoyl-acyl car-
rier protein reductase, InhA, an essential component in
mycolic acid biosynthesis [50]. Conversely, M. tuberculosis
is particularly sensitive to OS and hence requires KatG for
protection against ROS, including hydrogen peroxide. Para-
doxically, then, in shielding the bacterial cell from the toxic
activities of ROS, KatG also exposes the pathogen to the
anti-infective action of isoniazid [51].
Pretomanid, a bicyclic nitroimidazole, is a prodrug
that requires activation by a deazaﬂavin- (cofactor F420-)
dependent nitroreductase (Ddn) to produce three primary
metabolites, with des-nitroimidazole (des-nitro) being the
major antimycobacterial component [52]. The des-nitro
metabolite generates reactive nitrogen species, including
NO, and these provide anaerobic killing of M. tuberculosis
cells [53]. Hence, using a bacterial-encoded enzyme to acti-
vate the prodrug, pretomanid, creates intracellular levels of
nitrosative stress which are toxic to M. tuberculosis. The
thioamides, ethionamide, and its analogue, prothionamide,
are also prodrugs and are activated by an enzyme, EthA,
encoded by M. tuberculosis. EthA is a ﬂavoprotein monoox-
ygenase that catalyzes the NADPH- and O2-dependent
monooxygenation of thioamides [54]. The metabolites gen-
erated target InhA and inhibit mycolic acid synthesis in a
similar manner to isoniazid [55].
Table 1: Classiﬁcation of drugs for the treatment of MDR-TB.
Second-line
drug group
Drug type Speciﬁc drugs
Group A Fluoroquinolones
Levoﬂoxacin
Moxiﬂoxacin
Gatiﬂoxacin
Group B
Second-line
injectable agents
Amikacin
Capreomycin
Kanamycin
Streptomycin
Group C
Other core
second-line agents
Ethionamide/prothionamide
Cycloserine/terizidone
Linezolid
Clofazimine
Group D Group D1
Pyrazinamide
Ethambutol
High-dose isoniazid
Group D Group D2
Bedaquiline
Delamanid
Group D Group D3
p-Aminosalicylic acid
Imipenem-cilastatin
Meropenem
Amoxicillin-clavulanate
Thioacetazone
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7. Mechanisms of Oxidative Stress Tolerance
and Drug Resistance in
Mycobacterium tuberculosis
It is now known that M. tuberculosis shows marked sur-
vival within the host despite the toxic eﬀects of ROS, in
particular due to its ability to eﬀectively monitor and
counter redox signals through a number of mechanisms.
The interplay between oxidative stress and TB is depicted
in Figure 1. Several studies have implicated a key role of
cell wall-associated lipids (mycolic acids) in forming a
physical barrier to counter host-generated exogenous OS.
Utilising a combination of lipidomic and genomic approaches,
Portevin et al. reported signiﬁcant diﬀerences in the pro-
portion of structural variants of mycolic acids within and
between phylogenetic lineages of M. tuberculosis [56]. The
presence of diﬀerences in mycolic acids in the cell wall
could aﬀect the interaction of M. tuberculosis with the
host cells [56].
Furthermore, M. tuberculosis has also developed several
cellular mechanisms to counter the redox imbalance that
may also adversely aﬀect the eﬃcacy of frontline antitubercle
antibiotics. For instance, an increase in the mycobacterial
NADH/NAD+ ratio, throughmutation of ndhwhich encodes
a type II NADH dehydrogenase, confers coresistance to
isoniazid and ethionamide [57]. M. tuberculosis strains that
exhibit resistance to isoniazid and pretomanid also demon-
strate higher resistance to ROS compared to wild-type M.
tuberculosis (CDC1551 and CB3.3) [34, 36, 58]. These strains
were also found to have increased resistance towards perox-
ide and acidiﬁed nitrite [35, 58]. Several strains of M. tuber-
culosis are equipped to produce a speciﬁc protein, namely,
enhanced intracellular survival (Eis), which can detect ROS
and respond in a counteractive manner [59]. Moreover, M.
tuberculosis possesses proteasome (peroxiredoxin) that can
recognize, repair, and remove oxidative altered or damaged
proteins [60]. More recently, another peroxiredoxin system,
comprised of NADPH, thioredoxin reductase (TrxR), and
thioredoxin, has been shown to be highly eﬀective in protect-
ing M. tuberculosis against ROS stress [60]. M. tuberculosis
utilizes the thioredoxin (Trx) system for defense against OS
through its disulﬁde reductase activity regulating proteins’
dithiol/disulﬁde balance [61]. Betts et al. documented that
dormant M. tuberculosis under nutrient-limiting condi-
tions exhibit arrested growth, reduced respiration rate,
and increased tolerance against isoniazid, rifampicin, and
metronidazole [62].
M. tuberculosis also expresses alternative peroxidase
systems to maintain its virulence, including the expression
of alkyl hydroperoxide reductase subunit C (AhpC) [63].
AhpC relates to the peroxiredoxin family and contains three
cysteine residues in its active site and has been shown to be
Latent TB
Latent infection
Cysteine
↑↑Intra-
mycobacterial ROS
Bacterial
anti-oxidants Enzymes
So
dCSodA
KatG
↑ROS
↑RNI
DS-TB
MDR-TB
Unsuccessful
treatment
Active TB
First-line drugs (DS-TB)
Diagnosis; initiation of treatment
Activation of ‶pro-drugs″
+ supplements (cysteine, vitamin C)
↑ROS, ↑RNI
TB eradicated
AC2P36
Second-line drugs (MDR-, XDR-TB)
Vitamin C
Infection (via aerosol inhalation)
Active disease
TB relapse/
reactivation
Figure 1: Interplay of oxidative stress and tuberculosis. Infection with drug-susceptible or MDR-TB can lead to active clinical disease in
humans prompting diagnosis and the prescription of ﬁrst- or second-line drugs, respectively. TB disease also leads to increased
oxidative burden (ROS, RNI) in the lung that aids in the activation of TB prodrugs. Supplements such as vitamin C may augment
the treatment of TB by inhibiting the emergence of “persisters” through mechanisms including downregulation of mycobacterial
siderophore biosynthesis. Unsuccessful treatment can lead to subsequent TB relapse. Mycobacterium tuberculosis can also remain
dormant in the host during a latent TB infection. Administration of supplements (cysteine, vitamin C, and AC2P36) may provide
a pathway for inhibiting the reactivation of latent TB potentially by increasing the intramycobacterial OS and alteration in
“lipid/thiol” biosynthesis.
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overexpressed in M. tuberculosis exhibiting resistance to
isoniazid [64]. Mycobacteria utilize AhpC to detoxify
organic peroxides by reduction into less reactive alcohol
derivatives. Master et al. demonstrated that AhpC plays
an important role in the early stages of reactivation of
M. tuberculosis and/or upon transmission ofM. tuberculosis
to a new host [65].
M. tuberculosis also generates and secretes antioxidant
enzymes to persist in the abnormal redox environment; these
enzymes include SOD and KatG. Notably, M. tuberculosis
harbours one catalase (KatG) gene that accounts for catalase,
peroxidase, and peroxinitritase activity [66]. KatG is also a
known virulence factor inM. tuberculosis as it aids bacterium
to persist within the infected host tissues [67]. In addition to
KatG, M. tuberculosis also contains two metalloenzymes, an
iron-containing SOD (SodA or FeSOD) and a copper- and
zinc-containing SOD (SodC or CuZnSOD) [68, 69]. SodA
is expressed constitutively under homeostatic conditions
and is a major secretory protein of M. tuberculosis, which
has been shown to impart protection against superoxide in
in vitro experiments [70]. The expression of SodA is
enhanced by hydrogen peroxide exposure and nutrient
starvation [62]. SodC constitutes only a minor proportion
of mycobacterial superoxide dismutase activity; however,
SodC contains a lipoprotein-binding site, suggesting that it
is anchored on the cell wall, and has been demonstrated to
protect the bacterium from ROS [71].
Other recent advances have been made to understand
howM. tuberculosis survives an oxidative burden in the host.
For instance, Nambi et al. performed genome-wide genetic
interaction assays and demonstrated that SodA forms a
membrane-associated oxidoreductase complex with DoxX
(a membrane protein) and SseA (thiol oxidoreductase). This
SodA-DoxX-SseA complex links radical detoxiﬁcation with
cytosolic thiol homeostasis, and any abnormality in this
complex results in defective recycling of mycothiol and
accumulation of cellular oxidative damage [29]. Overall,
coordination between oxygen radical detoxiﬁcation and thiol
homeostasis is required for M. tuberculosis to encounter and
overcome the oxidative environment in the host.
Genomic analysis has revealed the presence of heme-
based redox sensors (DosS and DosT) in M. tuberculosis,
which has been reviewed elsewhere [72]. Kumar et al.
reported that DosS is rapidly autooxidized to met (Fe3
+)
form, whereas DosT exists in the O2-bound (oxy) form
[73]. Notably, O2, NO, and CO act as ligands for both DosS
and DosT [73]. The authors also proposed that DosS acts as
a redox sensor and DosT is primarily a hypoxia sensor [73].
It has been also reported that both DosS and DosT activate
transcriptional regulator DosR, leading to the induction of
the DosR regulon that aids the anaerobic survival of M.
tuberculosis and potentially leads to latent infection [74].
DosR regulon plays a critical role in the survival ofM. tuber-
culosis in the oxygen-depleted microenvironment (during
anaerobic dormancy), as well as rapid recovery of bacterial
reproducibility once the favorable growth conditions prevail
[75]. Mechanistically, Yang et al. have demonstrated that
deacetylation of DosR enhances its DNA-binding ability
and promotes the transcription of target genes (primarily
ﬂavin adenine dinucleotide binding, oxidoreductase activity,
and coenzyme binding), thus allowingM. tuberculosis to shift
to dormancy under hypoxia [76].
8. Potential New TB Therapies Targeting the
Oxidant :Antioxidant Balance
As mentioned, several front-line TB drugs need to be
activated ﬁrst to demonstrate their complete antitubercle
properties [57, 62]. The activation of these antimycobacterial
prodrugs is achieved by the action of oxidants released from
the host immune cells [77]. However, the evolution of
bacterial capability to neutralize the host’s OS has also led
to the nonactivation of these “inactivated” form of drugs to
exert their eﬀects on the pathogen. Therefore, it is necessary
to investigate and develop drugs with the potential to limit
the ability of M. tuberculosis to counter the host’s OS,
simultaneously enhancing the activation of prodrugs and
elimination of bacterium.
Interestingly, targeting cytochrome P450 enzymes in
M. tuberculosis has also been proposed as the source of a
potential new class of drugs for treating MDR-TB [78].
Similarly, targeting oxidative phosphorylation (NADH dehy-
drogenase, menaquinone biosynthesis, terminal oxidase,
and ATP synthase) with speciﬁc inhibitors (phenothiazine
derivatives, DG70, imidazopyridine amides, and diarylqui-
nolines), in combination with antitubercle drugs, is an
exciting novel avenue for short-term and eﬀective treatment
[79]. Notably, inhibiting bacterial oxidative phosphorylation
may also result in limiting the formation of “persisters” in
the host.
Treatment with cysteine (in a concentration- and time-
dependent manner with increased oxygen consumption)
has recently been shown to prevent the emergence of “per-
sisters” and isoniazid resistance by increasing the respiration
rates and thus promoting both OS and metabolism in the
pathogen [80]. Similar results were observed with rifampicin.
In infected murine macrophages, the combination of isonia-
zid and N-acetylcysteine (NAC) was found to be signiﬁcantly
more eﬀective in eliminating intracellular M. tuberculosis
than isoniazid alone [80]. In vitro experiments revealed that
cysteine (when added within 1 day of isoniazid treatment)
caused increasing delays in the growth of isoniazid-resistant
mutants, which was completely inhibited at highest concen-
tration (4mM). Interestingly, both isoniazid and the combi-
nation of isoniazid and cysteine resulted in similar bacterial
killing in a strain-independent manner (Mtb H37Rv, Mtb
Beijing, and Mtb CDC1551) for the ﬁrst 7 days; however,
only isoniazid/cysteine combination yielded approximately
6-log killing of the initial cultures after 3 weeks, without
development of isoniazid-resistant strains. Thus, the use of
supplements in combination with antitubercle drugs may
prevent the formation of “persister” bacteria, as well as
producing more eﬀective killing ofM. tuberculosis in shorter
time periods [81].
Several other potential combinatorial therapeutic
strategies are now being investigated. Vilchèze et al. reported
that vitamin C (4mM) speciﬁcally sterilizes in vitro cultures
of M. tuberculosis, including drug-susceptible (H37Rv) and
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MDR-resistant (mc24997) and extensively drug-resistant
(TF275) variants of bacillus. The transcriptional proﬁle of
vitamin C-treated M. tuberculosis revealed downregulation
in the mbtD gene (biosynthesis of siderophore) [82]. The
antitubercle activity of vitamin C depends upon the high
concentration of ferrous ion leading to increased free ions
levels, both intracellularly (50–75%) and extracellularly (4-
fold). Vitamin C treatment (4mM) also increased ROS
(superoxide, hydrogen peroxide, and hydroxyl radicals) pro-
duction (~3-fold) via the Haber-Weiss and Fenton reactions,
which can result in DNA fragmentation measured by the ter-
minal deoxynucleotidyl transferase-mediated dUTP-biotin
nick end labelling (TUNEL) assay [82]. The eﬀects of vitamin
C were not observed when culturing M. tuberculosis in
anaerobic conditions (oxygen level < 0 001%), suggesting a
prooxidant eﬀect of vitamin C [82]. In addition, mycothiol-
deﬁcient strain of M. tuberculosis (ΔmshA), hypersensitive
to OS, showed rapid growth reduction in the presence of
vitamin C, conﬁrming the role of the oxidative process in
its bactericidal activity [82]. Vitamin C treatment also
aﬀected the FASI (eukaryotic-like fatty acid synthase type I)
potentially leading to altered lipid biosynthesis in an
NADPH concentration-dependent manner. Collectively,
vitamin C exhibits bactericidal activity against M. tuberculo-
sismost likely due to its prooxidant activity, at least in in vitro
cultures [82].
Recently, Vilchèze et al. have also shown that addition of
vitamin C (1mM) to isoniazid/rifampicin sterilized the
in vitro cultures of drug-susceptible M. tuberculosis more
rapidly than the drugs alone (~1 week). Similar eﬀects were
observed with even second-line TB drugs, namely, ﬂuoro-
quinolone oﬂoxacin (OF), the injectable kanamycin (Km),
and ETH [83], where addition of vitamin C reduced the
sterilization time by 9 days compared to drugs alone [83].
Moreover, the authors also demonstrated that combining
vitamin C with isoniazid and rifampin reduced the bacterial
burden in the lungs of mice infected with M. tuberculosis
over a shorter time frame than isoniazid and rifampin
combination only [83]. Brieﬂy, buﬀered aqueous 1.7M solu-
tion (3 g/kg) of vitamin C was intraperitoneally administered
to CBA/J female mice and infected with either low (28 CFUs)
or high (105 CFUs) doses ofM. tuberculosis (H37Rv) via the
aerosol route. The mice receiving lower infective dose and
treated with the combination of isoniazid/rifampicin/vitamin
C exhibited lower lung bacterial burden (~one log) compared
to mice treated with isoniazid/rifampicin in average at four
weeks post-infection. Post-6-week treatment,M. tuberculosis
was recovered from the lungs of one mouse in both isoniazid/
rifampicin/vitamin C and isoniazid/rifampicin groups. The
mice receiving higher infective dose showed a signiﬁcantly
lower bacterial recovery from lung only after 6 weeks of
treatment in the isoniazid/rifampicin/vitamin C group [83].
The studies on the eﬃcacy of vitamin C supplementation in
TB outcomes have been largely positive (both in humans
and animal models); however, focused studies addressing
several pointed questions (vitamin C quantity, spectrum of
activity, etc.) in clinical trials could provide deﬁnitive
rationale and the underlying mechanism of action for the
treatment of TB [84].
Another compound, AC2P36 (5-chloro-N-(3-chloro-
4-methoxyphenyl)-2-methylsulfonylpyrimidine-4-carboxa-
mide), has been shown to kill M. tuberculosis by directly
depleting the amount of free thiols, especially at acidic
pH (5.7), and to enhance the bactericidal activity of
commonly used antitubercle drugs, including isoniazid
and clofazimine [85]. The antitubercle activity of AC2P36
seems to be associated with “thiol stress,” which leads
to increased accumulation of intracellular ROS, at acidic
pH [85].
Collectively, these studies highlight the crucial roles
of oxidant : antioxidant balance in limiting and treating
M. tuberculosis infections. The utilization of relatively
safe and inexpensive therapeutic supplements, such as
vitamin C or cysteine, may aid in bacterial killing through
increasing ROS burden in the bacterium and alterations
in the lipid/thiol biosynthesis in a shorter time frame
and without the formation of a drug-resistant “persister”
population in the host. Future studies should also focus
on developing novel strategies to target the DosS/DosT
mechanisms as well as mycolic acid biosynthesis for M.
tuberculosis survival, in combination with existing antibi-
otics that may pave the way for improved therapies to treat
the disease.
9. Conclusions
Oxidative stress mediated by host cells, especially macro-
phages, plays a pivotal role to prevent the vicious cycle of
M. tuberculosis. However, certain strains of M. tuberculosis
are known to be resistant against the inhibitory eﬀects of
the oxidative burst produced by macrophages, primarily
via the presence of lipids, proteins, enzymes, and antioxi-
dant defense systems, like SOD, KatG, and DosR regulon,
within the mycobacteria. These act in a counteractive
mode against OS. These antioxidative mechanisms also
aﬀect the antibiotic drug treatment. Various research ﬁnd-
ings have led to a greater understanding of the eﬀects of
both drug-susceptible and MDR-TB strains and the gener-
ation of novel therapeutic interventions to tackle the
response of mycobacteria towards oxidative burden. The
research has just only begun to assess the eﬀects of a
combination of therapies, including antitubercle antibiotics
and agents targeting the oxidant : antioxidant axis, which
may prove beneﬁcial in eliminating the pathogen from the
host in a shorter time frame.
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